Key Highlights
- An executive order signed by President Trump aims to expedite psychedelic therapy research and accessibility for PTSD and severe mental health conditions.
- COMPASS Pathways (CMPS) experienced a 25% surge during premarket hours after the announcement.
- The company disclosed successful results from two Phase 3 clinical studies evaluating COMP360 synthetic psilocybin for depression that resists conventional treatments.
- A rolling submission to the FDA for COMP360 is currently in progress.
- Financial analysts from Oppenheimer, Jefferies, and RBC issued optimistic assessments, highlighting accelerated commercialization prospects.
On April 20, 2026, President Trump issued an executive order mandating federal agencies to fast-track research initiatives and broaden availability of psychedelic compounds currently utilized internationally for treating PTSD and severe psychiatric disorders.
The announcement triggered significant gains across psychedelic pharmaceutical stocks during premarket sessions.
COMPASS Pathways (CMPS) emerged as the sector leader with a 25% increase. AtaiBeckley (ATAI) climbed 22%, Definium Therapeutics (DFTX) advanced 20%, while GH Research (GHRS) and Cybin (HELP) both jumped 17%.
The timing of the executive order coincided with COMPASS maintaining significant clinical progress.
Earlier in the month, the biotechnology firm announced successful outcomes from two Phase 3 clinical studies examining COMP360, its synthetic psilocybin treatment designed for treatment-resistant depression (TRD). The company has initiated a rolling FDA submission process.
COMP360 previously achieved positive late-stage trial results, with the organization highlighting impressive efficacy and safety profiles. The rolling submission approach enables the FDA to evaluate completed segments prior to receiving the complete application — a strategy that potentially reduces overall review duration.
Wall Street Responds Favorably
Oppenheimer’s Jay Olson characterized the executive order as “a structural inflection for the US psychedelics sector by facilitating research, regulatory timelines, and patient access.” Olson identified Atai Beckley, COMPASS Pathways, and Definium Therapeutics as possessing “differentiating advantages.”
Jefferies analyst Andrew Tsai highlighted coordination throughout the executive branch — encompassing Trump, HHS, FDA, and the VA — stating “investor mindshare should rise meaningfully ahead of potential approvals in 2027–30.” He noted that “the path to commercialization could be even faster now.”
Brian Abrahams from RBC described the order as an acceleration of psychedelics representing “the key next wave of mental health treatments,” identifying Definium Therapeutics, COMPASS Pathways, and GH Research as primary beneficiaries.
Financial Projections and Outlook
Revenue and earnings projections for COMPASS Pathways demonstrate considerable variation among analysts. Bullish forecasts anticipate $193.1 million in revenue alongside $24.2 million in earnings by 2029. Conservative estimates place revenue around $59.5 million with $6.5 million in earnings for the same timeframe.
This substantial divergence underscores genuine uncertainty regarding approval specifications, insurance coverage, and treatment facility infrastructure development.
COMPASS continues operating with significant cash expenditure, necessitating successful commercialization within a viable timeframe to prevent additional shareholder dilution or capital raises.
The organization’s immediate priorities include FDA evaluation of COMP360 for TRD, with potential subsequent applications targeting PTSD treatment.
By April 20, 2026, CMPS stock had climbed over 40% as regular trading commenced, building upon the premarket momentum.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
